$1.20
-0.26 (-17.81%)
Open$1.46
Previous Close$1.46
Day High$1.46
Day Low$1.20
52W High$13.20
52W Low$1.06
Volume—
Avg Volume62.7K
Market Cap11.01M
P/E Ratio—
EPS$-5.13
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,331.7% upside
Current
$1.20
$1.20
Target
$29.18
$29.18
$17.82
$29.18 avg
$40.31
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.45M | 8.50M | 8.91M |
| Net Income | 239.2K | 243.9K | 245.4K |
| Profit Margin | 2.5% | 2.9% | 2.8% |
| EBITDA | 403.0K | 435.3K | 434.6K |
| Free Cash Flow | 313.2K | 273.2K | 249.3K |
| Rev Growth | +19.1% | +23.4% | +6.1% |
| Debt/Equity | 0.60 | 0.55 | 0.53 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |